Compare iShares Bitcoin Trust (IBIT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs Novartis AG — how do they compare? iShares Bitcoin Trust trades at $46.55 (market cap $67.31B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 4× iShares Bitcoin Trust's market cap, and Novartis AG pays a 3.31% dividend while iShares Bitcoin Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 40 Days and Novartis AG for 82 Days on average.
| IBIT | NVS | |
|---|---|---|
Market Cap | $67.31B | $268.57B |
Volume | 56,154,544 | 1,532,573 |
Sector | Crypto-linked | Health |
52-Week High | $66.20 | $168.62 |
52-Week Low | $33.29 | $121.80 |
Typical Hold Time | 40 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $46.26, down 2.01% today amid bearish technical signals. The stock faces resistance at $47-$48 with support at $44-$46. Recent news highlights significant institutional inflows, including a $196 million single-day inflow on October 1, 2026, reflecting renewed investor confidence despite current price weakness.
The outlook remains cautious with technical indicators showing bearish momentum, though strong institutional interest suggests potential recovery. Key risks include market volatility and ETF fee structures, while analyst sentiment appears mixed with ongoing monitoring of Bitcoin market dynamics influencing stock performance.
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
